Departments of Radiology and Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Theranostics. 2018 Dec 1;8(22):6352-6354. doi: 10.7150/thno.31515. eCollection 2018.
The receptor for advanced glycation end-products (RAGE) is implicated in multiple disease states such as cancer, diabetes and neurodegenerative disorders, and RAGE inhibitors are being explored as potential new therapies in such cases. Despite the known role RAGE plays in these conditions, there remains an urgent need for a molecular imaging agent that can accurately quantify RAGE levels , aid in validation of RAGE as a biomarker and/or therapeutic target, and support development of new RAGE inhibitors. This editorial highlights a multimodal nanoparticle-based imaging agent targeted at RAGE that was recently developed by Konopka and colleagues ( 2018; 8(18):5012-5024. doi:10.7150/thno.24791).
晚期糖基化终产物受体（RAGE）与多种疾病状态有关，如癌症、糖尿病和神经退行性疾病，并且 RAGE 抑制剂正被探索作为这些情况下的潜在新疗法。尽管已知 RAGE 在这些情况下的作用，但仍迫切需要一种分子成像剂，能够准确地定量 RAGE 水平，有助于验证 RAGE 作为生物标志物和/或治疗靶点，并支持新的 RAGE 抑制剂的开发。这篇社论强调了一种最近由 Konopka 及其同事开发的针对 RAGE 的多模态纳米颗粒成像剂（2018；8（18）：5012-5024。doi:10.7150/thno.24791）。
